I Priority Products to be Manufactured by Nigeria Diagnostics in Plant 1:

Nigeria Diagnostics will manufacture in its Plant 1, phase 1 stage, 80 million/year rapid diagnostic test kits covering the following infections and diseases:
1.Hepatitis C virus (HCV)
2.Human Immunodeficiency virus (HIV)
3.Malaria virus
4.H. pylori virus
5.Tuberculosis
6.Hepatitis B virus
7. Human Chorionic Gonadotropin (HCG).

Nigeria Diagnostics will expand its portfolio, to include technology transfer and local manufacturing of the following diagnostic rapid test kits at its stage 2:
8.Colorectal Cancer
9.Cancer (CA125, CA15-3, CA72-4)
10.Hormone (B-hcg, LH, FSH)
11.Cardiac (Troponin-I)
12.STD (HPV, Trichomonas Vaginalis, Mycoplasma Genitalium, Chlamydia Trachomatis, Neisseria Gonorrhea
13.Blood Born Infection (Syphilis Ab)
14.Respiratory Virus (Influenza A/B, Covid19 Ag, RSV Ag, Streptococcus Ag
15.Adeno Ag, Infection (Toxo IgG/IgM, CMV IgG/IgM, Rubella IgG/IgM, Typhoid IgG/IgM
16.Tropical Emerging Infections (Dengue, Zika, Chikungunya, Yellow Fever).

Total manufacturing capacity will reach at peak production 400 million test kits per year. Nigeria Diagnostics will conduct its manufacturing and all GMP activities in compliance with all applicable regulatory requirements where its products are marketed, including but not limited to, Nigeria, Africa, the Middle East, Europe, Asia and South and North America. Nigeria Diagnostics will conduct its own development, validation, testing and stability studies to support the quality of the products it manufactures.
I Priority Products to be Manufactured by Nigeria Diagnostics in Plant 2:

Nigeria Biologics, as part of Project Black Shield, will focus on the fill-finish manufacturing of critical vaccines and biologics to address pressing healthcare needs in Nigeria and in the continent. This initiative aims to bolster the availability of essential medicines and enhance healthcare delivery across Nigeria and Africa. Key products and their impacts include:
Initial Manufacturing Focus:
1.Hexavalent Vaccine: Offering protection against six serious diseases (diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B) in a single injection, this vaccine will play a crucial role in comprehensive childhood immunization programs in Nigeria.
2.HPV Vaccine: Preventing cancers and genital warts caused by the Human Papillomavirus, the HPV vaccine will significantly reduce the incidence of HPV-related diseases, particularly cervical cancer, in the region.
3.PCV Vaccine: The Pneumococcal Conjugate Vaccine (PCV) will help prevent pneumococcal diseases, such as pneumonia and meningitis, which are major causes of morbidity and mortality among children around the world.
4.Bevacizumab: An essential biologic used in the treatment of various cancers, including colorectal, lung, kidney, and glioblastoma, providing critical care for cancer patients.
5.Adalimumab: Used to treat autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis, improving the quality of life for patients with chronic inflammatory diseases.

Expansion of Manufacturing Portfolio:
As Nigeria Biologics grows, it will expand its portfolio through technology transfer and local manufacturing of additional vaccines and biologics, including:
1.Rotavirus Vaccine: Preventing severe diarrhea in infants and young children, this vaccine will reduce child mortality and morbidity rates.
2.Measles Vaccine: Essential for preventing measles infections, a significant cause of child mortality, with administration at 9 and 15 months.
3.Yellow Fever Vaccine: Critical for preventing yellow fever, particularly in endemic regions, administered at 9 months.
4.Trastuzumab: Used for HER2-positive breast cancer, providing targeted therapy for better treatment outcomes.
5.Rituximab: Treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and some autoimmune diseases, this biologic will enhance cancer treatment options.
6.Infliximab: Used for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis, further expanding therapeutic options for autoimmune conditions.
I Commitment to Quality and Compliance:
Nigeria Biologics is dedicated to adhering to the highest standards of quality and regulatory compliance. All manufacturing processes will be conducted in compliance with Good Manufacturing Practices (GMP) and other applicable regulatory requirements in target markets. This commitment ensures the production of safe, effective, and high-quality vaccines and biologics. By establishing robust manufacturing capabilities for these critical healthcare products, Nigeria Biologics aims to enhance healthcare delivery, improve patient outcomes, and contribute to the self-reliance and sustainability of Nigeria's healthcare system, supporting proactively the Presidential Unlocking the Helathcare Value Chain initiative.